Target |
Pharma. Ref. |
Biology |
Pathologies |
Bibliography |
Code |
Name |
PDF |
|
|
|
|
|
|
|
|
|
Sodium channels |
Tetrodotoxin |
Action Potential genesis and propagation |
- Epilepsy
- Hungtington's Disease
- Hyperactivity and Attention Deficit Disorders
- Multiple Sclerosis
- Neuropathic Pain
- Pain |
- Meisler & Kearney (2005), J. Clin. Invest., 115, 2010-2017
- Jentsch, T. et al (2004), Nature Cell. Biol., 11, 1039-1047
- Devor, M. (2006), J. Pain, 7(1 Suppl 1), S31-S37
|
P-001 |
Fast sodium channel inhibition |
|
AMPA/Kainate receptors |
NBQX |
Glutamatergic synaptic transmission |
- Epilepsy
- Amyotrophic Lateral Sclerosis
- Stroke |
- Catarzi, D et al. (2006), Med. Res. Rev. 27, 239-278.
- Namba, T et al. (1994), Brain Res., 638, 36-44.
- Sheardown, MJ (1993), Stroke, 24, 146-147.
|
P-002 |
AMPA- mediated synaptic transmission |
|
NMDA receptors |
D-AP5 |
Long-Term Potentiation |
- Hungtington's Disease
- Parkinson's Disease
- Schizophrenia |
- Duncan, GE et al. (1999) Brain Res. Brain Res. Rev., 29, 250-264.
- Malenka, RC & Nicoll, RA (1999), Science, 285, 1870-1874.
- Samanta, MK et al. (2006), Am. J. Ther., 13, 516-526.
- Bonuccelli, U & Del Dotto, P (2006), Neurology, 67(7 Suppl 2), S30-S38.
|
P-003 |
NMDA receptors competitive antagonist |
|
GABA-A receptors |
Bicuculline |
Epileptiform activity |
- Epilepsy
- Anxiety
- Sleep Disorders |
- Olsen RW, Ban M, Miller T (1976), Brain Res 102:283-299.
- Treiman DM (2001), Epilepsia, 42 Suppl 3, 8-12.
|
P-004 |
GABA-A receptors - Network Excitability |
|
GABA-A receptors |
Ganaxolone |
Allosteric modulation of GABA-A |
- Epilepsy
- Anxiety
- Sleep Disorders |
- Belelli & Lambert (2005), Nature Neurosci., 6, 565-575.
- Rogawski, MA (2006), Epilepsy Res., 69, 273-294.
- Stell, BM et al. (2003), Proc. Natl. Acad. Sci. (USA), 100, 14439-14444
|
P-005 |
Neurosteroids / GABA-A receptors |
|
Phasic GABA-A receptors |
Gabazin (SR-95531) |
GABA-A receptor-mediated fast synaptic transmission |
- Epilepsy
- Anxiety
- Sleep Disorders |
- Bai, D et al. (2001), Mol. Pharmacol., 59, 814-824.
- Stell, BM & Mody, I (2002), J. Neurosci., 22, RC223.
- Yeung, JF et al. (2003), Mol. Pharmacol., 63, 2-8.
- Semyanov et al. (2004), Trends Neurosci., 27, 262-269.
- Cossart, R. et al. (2005), Trends Neurosci., 28, 108-115.
- Farrant, M & Nusser, Z. (2005), Nat. Rev. Neuroci., 6, 215-229.
|
P-006 |
Inhibition of phasic GABA-A receptors |
|
mGluR1 & mGluR5 receptors |
DHPG |
LTD induced by mGluR1/mGluR5 activation |
- Epilepsy
- Pain
- Stroke
- Anxiety
- Addiction
- Neurodegeneration |
- Palmer, MJ et al. (1997), Neuropharmacology, 36, 1517-1532.
- Fitzjohn, SM et al. (2001), J. Physiol., 537, 421-430.
- Rammes, G et al. (2003), J. Physiol., 546 (Part 2), 455-460
- Gallagher, SM et al. (2004), J. Neurosci., 24, 4859-4864.
- Volk, LJ et al. (2006), J. Neurophysiol., 95, 2427-2438.
- Lea, PM & Faden, AI (2006), CNS Drug Rev., 12, 149-166.
|
P-007 |
DHPG - induced LTD |
|
AMPA/Kainate receptors |
Kainate |
Excitotoxicity |
- Epilepsy
- Pain
- Stroke
- Cognitive Disorders |
- Dingledine, R et al. (1999), Pharm. Rev., 51, 7-61.
- Lynch, G (2004), Cur. Op. Pharmaco., 4, 4-11.
- Weiser, T (2005), Curr. Drug Targets CNS Neurol. Disord., 4, 153-159.
- Lerma, J (2006), Cur. Op. Pharmaco. 6, 89-97.
- Pinheiro, P & Mulle, C (2006), Cell Tissue Res., 326, 547-482.
|
P-008 |
AMPA/Kainate receptors-mediated excitotoxicity |
|
L-type VDCC |
Nifedipine |
Modulation of synaptic transmission by VDCC |
- Epilepsy
- Stroke
- Cognitive Disorders
- Depression |
- O'Regan, MH et al. (1991), Exp. Brain Res., 84, 224-228.
- Disterhoft, JF et al. (1993), Clin. Neuropharmacol., 16 suppl.1, S12-S24.
- Catterall, WA (2000), Annu. Rev. Cell. Dev. Biol.,16, 521-555.
- Godukhin, O et al. (2002), Neuropharmacology, 42, 459-466.
- Bourinet, E & Zamponi, GW (2005), Curr. Top. Med. Chem., 5, 539-546.
- Striessnig, J et al. (2006), Biochem. Soc. Trans., 34, 903-909.
|
P-009 |
L-type calcium channels / Synaptic Transmission |
|
Acetylcholinesterase |
Physostigmine (Eserine) |
cholinergic modulation of glutamate neurotransmission |
- Hyperactivity and Attention Deficit Disorders
- Alzheimer's Disease
- Cognitive Disorders
- Dementia |
- Wilkinson, DG (1999), Expert Opin. Pharmacother., 1, 121-135.
- Colgin et al. (2003), J. Neurophysiol., 90, 2358-2366.
- Lleo, A et al. (2005), Annu. Rev. Med., 57, 513-533.
- Coulthard, E et al. (2006), Curr. Opin. Neurol., 19, 613-618.
|
P-010 |
Cholinergic transmission - Alzheimer's disease |
|
NMDA & Nicotinic receptors |
Memantine |
Long-Term Potentiation / Memory |
- Alzheimer's Disease
- Parkinson's Disease
- Dementia |
- Parsons, CG et al. (1993), Neuropharmacology, 32, 1337-1350.
- Parson, CG et al. (1996), Eur. J. Neurosci., 8, 446-454.
- Buisson & Bertrand (1998), Mol. Pharmacol., 53, 555-563.
- Lipton, SA (2004), NeuroRx, 1, 101-110.
- Ringman, JM & Cummings, JL (2006), Behav. Neurol., 17, 5-16.
|
P-011 |
NMDA & Nicotinic receptors / Alzheimer's & Parkinson's diseases |
|
H3 Histamine receptor |
R-alpha-methylhistamine |
Pre-synaptic H3 receptor |
- Epilepsy
- Hyperactivity and Attention Deficit Disorders
- Alzheimer's Disease
- Parkinson's Disease
- Schizophrenia
- Anxiety
- Sleep Disorders
- Cognitive Disorders
- Obesity |
- Brown RE, Reymann KG (1996). J Physiol 496 ( Pt 1):175-184.
- Brown RE, Stevens DR, Haas HL (2001). Prog Neurobiol 63:637-672.
- Esbenshade TA, Fox GB, Cowart MD (2006). Mol Interv 6:77-88, 59.
- Passani MB, Lin JS, Hancock A, Crochet S, Blandina P (2004). Trends Pharmacol Sci 25:618-625.
- Witkin JM, Nelson DL (2004). Pharmacol Ther 103:1-20.
- Yoshimoto R, Miyamoto Y, Shimamura K, Ishihara A, Takahashi K, Kotani H, Chen AS, Chen HY, Macneil DJ, Kanatani A, Tokita S (2006). Proc Natl
Acad Sci U S A 103:13866-13871.
|
P-012 |
H3 Histamine receptor-dependent depression in Dentate Gyrus |
|
H1 and H2 Histamine receptors |
Histamine |
CA1 pyramidal neurons spontaneous activity |
- Pain
- Anxiety
- Sleep Disorders
- Cognitive Disorders |
- Brown RE, Fedorov NB, Haas HL, Reymann KG (1995).
Neuropharmacology 34:181-190.
- Brown RE, Stevens DR, Haas HL (2001). Prog Neurobiol 63:637-672.
- Haas HL, Greene RW (1986) Exp Brain Res 62:123-130.
- Selbach O, Brown RE, Haas HL (1997). Neuropharmacology 36:1539-1548.
|
P-013 |
Histamine receptors mediated increase of CA1 pyramidal neurons firing |
|
mGluR2 receptors |
DCG-IV |
Pre-synaptic mGluR2 receptors |
- Anxiety
- Addiction
- Obsessive-Compulsive Disorders |
- Smialowska M, Wieronska JM, Domin H, Zieba B (2007). Neuropsychopharmacology 32:1242-1250.
- Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD (2005). Nat Rev Drug Discov 4:131-144.
- Zhao Y, Dayas CV, Aujla H, Baptista MA, Martin-Fardon R, Weiss F (2006). J Neurosci 26:9967-9974.
|
P-014 |
mGluR2-mediated depression of synaptic transmission at MPP synapses |
|
D1/D5 Dopamine receptors |
SCH23390 |
Dopaminergic modulation of synaptic transmission |
- Parkinson's Disease
- Cognitive Disorders |
- Frey U, Matthies H, Reymann KG, Matthies H (1991). Neurosci Lett 129:111-114.
- Huang YY, Kandel ER (1995). Proc Natl Acad Sci U S A 92:2446-2450.
- Lemon N, Manahan-Vaughan D (2006). J Neurosci 26:7723-7729.
|
P-015 |
Dopamine-induced increase of synaptic transmission and plasticity |
|
K+ channel |
Phenytoin / Carbamazepine |
In vitro epilepsy model |
- Epilepsy |
- Perreault P, Avoli M (1991). J Neurophysiol 65:771-785.
- Traub RD, Colling SB, Jefferys JG (1995). J Physiol 489 ( Pt 1):127-140.
- Yonekawa WD, Kapetanovic IM, Kupferberg HJ (1995). Epilepsy Res 20:137-150.
|
P-016 |
Model of 4-AP-induced epilepsy |
|
NMDA receptor |
Phenytoin / Carbamazepine |
In vitro epilepsy model |
- Epilepsy |
- Arias RL, Bowlby MR (2005). Brain Res 1047:233-244.
- Armand V, Rundfeldt C, Heinemann U (2000) . Epilepsia 41:28-33.
- Tancredi V, Hwa GG, Zona C, Brancati A, Avoli M (1990) . Brain Res 511:280-290.
|
P-017 |
Model of low-magnesium-induced epilepsy |
|
GABA-A receptor |
Somatostatin |
In vitro epilepsy model |
- Epilepsy |
- Debanne D, Thompson SM, Gühwiler BH.(2006) Epilepsia Feb;47(2):247-56.
- Tallent MK, Siggins GR (2007), J.physiol Apr;81(4):1626-35.
- Treiman DM (2001), Epilepsia, 42 Suppl 3, 8-12.
|
P-018 |
Model of bicuculline-induced epilepsy |
|
GABA-A / M1muscarinic receptors |
Diazepam |
In vitro epilepsy model |
- Epilepsy |
- Behrends JC, ten Bruggencate G (1993). J Neurophysiol 69:626-629.
- Cruickshank JW, Brudzynski SM, McLachlan RS (1994). Brain Res 643:125-129.
- Harrison PK, Sheridan RD, Green AC, Scott IR, Tattersall JE (2004). J Pharmacol Exp Ther 310:678-686.
- McDonough JH, Jr., Zoeffel LD, McMonagle J, Copeland TL, Smith CD, Shih TM (2000). Epilepsy Res 38:1-14.
|
P-019 |
Model of cholinergic-induced epilepsy |
|
NMDA receptors |
D-AP5 |
Pure NMDA-mediated EPSP |
- Alzheimer's Disease
- Parkinson's Disease
- Schizophrenia
- Ischemia |
- M. R. Foy et al. (1999), J Neurophysiol 81:925-929.
- Duncan, GE et al. (1999) Brain Res. Rev., 29, 250-264.
- Malenka, RC & Nicoll, RA (1999), Science, 285, 1870-1874.
- Samanta, MK et al. (2006), Am. J. Ther., 13, 516-526.
- Bonuccelli, U & Del Dotto, P (2006), Neurology, 67(7 Suppl 2), S30-S38.
|
P-020 |
NMDA receptor modulators |
|
GABA-A receptors |
Diazepam |
Paired-pulse inhibition |
- Epilepsy
- Schizophrenia
- Anxiety
- Sleep Disorders |
- Mühler H (2006), Cell Tissue Res., 326(2):505-16.
- Rogawski, MA (2006), Epilepsy Res., 69, 273-294.
- Wease KN, Davies SN (2005), BMC Neurosci., Nov 23;6:66.
|
P-021 |
GABAergic-mediated inhibition of synaptic transmission |
|
NA |
Kainate & Carbamazepine |
CA1 pyramidal neurons spontaneous activity |
- Epilepsy |
- Day IP, Goudie J, Nishiki K, Williams PD (1995). Toxicol Lett. Apr;76(3):239-43.
- Easter A, Bell ME, Damewood JR Jr, Redfern WS, Valentin JP, Winter MJ, Fonck C, Bialecki RA.
(2009). Drug Discov Today.Sep;14(17-18):876-84. Jun 21. Review.
- Ketelaars SO, Gorter JA, van Vliet EA, Lopes da Silva FH, Wadman WJ. (2001). Neuroscience. 105(1):109-20.
|
P-022 |
Characterization of pro- or anti-convulsive properties |
|
M1 Muscarinic acetylcholine receptors |
Carbachol & Pirenzepine |
CA1 pyramidal neurons spontaneous activity |
- Alzheimer's Disease
- Schizophrenia |
Langmead CJ, Watson J, Reavill C (2008). Pharmacol Ther.
Feb;117(2):232-43. Review.
- Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM (2006). Neuron Mar 2;49(5):671-82.
- Watt ML, Schober DA, Hitchcock S, Liu B, Chesterfield AK, McKinzie D, Felder CC (2011). J Pharmacol Exp Ther, Aug;338(2):622-32.
|
P-023 |
Cholinergic receptors-mediated increase of CA1 pyramidal neurons firing |
|
MEA (Multi-Electrode Array)
